Bcl-2: Live and let die.

Abstract:

:Recent findings from our laboratory provide the first indication that overexpression of Bcl-2 in Eµ-myc transgenic cells enhances tumor immunosurveillance by inducing NKG2D ligands. Initial evidence suggests that this model is relevant to human patients. Thus, antitumor therapies that target Bcl-2 harbor the risk of reducing tumor immunogenicity.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Putz EM,Schuster C,Sexl V

doi

10.4161/onci.19536

subject

Has Abstract

pub_date

2012-08-01 00:00:00

pages

749-750

issue

5

eissn

2162-4011

issn

2162-402X

pii

2012ONCOIMM0037

journal_volume

1

pub_type

杂志文章
  • CCL3 augments tumor rejection and enhances CD8+ T cell infiltration through NK and CD103+ dendritic cell recruitment via IFNγ.

    abstract::Inflammatory chemokines are critical contributors in attracting relevant immune cells to the tumor microenvironment and driving cellular interactions and molecular signaling cascades that dictate the ultimate outcome of host anti-tumor immune response. Therefore, rational application of chemokines in a spatial-tempora...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1393598

    authors: Allen F,Bobanga ID,Rauhe P,Barkauskas D,Teich N,Tong C,Myers J,Huang AY

    更新日期:2017-11-20 00:00:00

  • mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

    abstract:INTRODUCTION:Vaccination with dendritic cells (DCs) has generally not fulfilled its promise in cancer immunotherapy due to ineffective translation of immune responses into clinical responses. A proposed reason for this is intrinsic immune regulatory mechanisms, such as regulatory T cells (Tregs). A metronomic regimen o...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1207842

    authors: Borch TH,Engell-Noerregaard L,Zeeberg Iversen T,Ellebaek E,Met Ö,Hansen M,Andersen MH,Thor Straten P,Svane IM

    更新日期:2016-07-08 00:00:00

  • A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer.

    abstract::Cancer immunotherapy continues to make headway as a treatment for advanced stage tumors, revealing an urgent need to understand the fundamentals of anti-tumor immune responses. Noteworthy is a scarcity of data pertaining to the breadth and specificity of tumor-specific T cell responses in metastatic breast cancer. Aut...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1685300

    authors: DeVette CI,Gundlapalli H,Lai SA,McMurtrey CP,Hoover AR,Gurung HR,Chen WR,Welm AL,Hildebrand WH

    更新日期:2019-11-29 00:00:00

  • Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.

    abstract::Kynurenine formation by tryptophan-catabolic indoleamine-2,3-dioxygenase 1 (IDO1) plays a key role in tumor immune evasion and inhibition of IDO1 is efficacious in preclinical models of breast cancer. As the response of breast cancer to immune checkpoint inhibitors may be limited, a better understanding of the express...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1274477

    authors: Dewi DL,Mohapatra SR,Blanco Cabañes S,Adam I,Somarribas Patterson LF,Berdel B,Kahloon M,Thürmann L,Loth S,Heilmann K,Weichenhan D,Mücke O,Heiland I,Wimberger P,Kuhlmann JD,Kellner KH,Schott S,Plass C,Platten M,Gerhä

    更新日期:2017-01-03 00:00:00

  • Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis.

    abstract::Purpose: Tumor development has been closely linked to tumor microenvironment, particularly in terms of myeloid-derived suppressive cells (MDSCs), a heterogeneous population of immature myeloid cells that protect tumors from elimination by immune cells. Approaches aimed at blocking MDSC accumulation could improve cance...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1442167

    authors: Qin G,Lian J,Huang L,Zhao Q,Liu S,Zhang Z,Chen X,Yue D,Li L,Li F,Wang L,Umansky V,Zhang B,Yang S,Zhang Y

    更新日期:2018-03-13 00:00:00

  • CAR-T cells are serial killers.

    abstract::Chimeric antigen receptor (CAR) T cells have enjoyed unprecedented clinical success against haematological malignancies in recent years. However, several aspects of CAR T cell biology remain unknown. We recently compared CAR and T cell receptor (TCR)-based killing in the same effector cell and showed that CAR T cells ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1053684

    authors: Davenport AJ,Jenkins MR,Ritchie DS,Prince HM,Trapani JA,Kershaw MH,Darcy PK,Neeson PJ

    更新日期:2015-06-01 00:00:00

  • The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

    abstract::We have shown that melanoma-derived factors alter the function of differentiated tissue-resident dendritic cells (DC) in a tumorigenicity-dependent manner. Soluble factors, including TGFβ1 and VEGF-A, contributed to dendritic cell dysfunction associated with a highly-aggressive melanoma and conferred a phenotype upon ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1069462

    authors: Hargadon KM

    更新日期:2015-08-12 00:00:00

  • Fbxw7 suppresses cancer metastasis by inhibiting niche formation.

    abstract::Fbxw7 has been identified as an oncosuppressor protein in many types of cancer. We have recently shown that loss of Fbxw7 in bone marrow-derived stromal cells (BMSCs) promotes cancer metastasis by increasing production of the chemokine CCL2, which attracts monocytic myeloid-derived suppressor cells (Mo-MDSCs) and macr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1022308

    authors: Yumimoto K,Nakayama KI

    更新日期:2015-06-03 00:00:00

  • ATM activation mediates anticancer immunosurveillance by natural killer and T cells.

    abstract::The DNA damage response (DDR), which is frequently activated in cancer cells, has been proposed to operate as an early barrier against oncogenesis. We have recently shown that ATM mediates the spontaneous regression of Eμ-myc-driven murine B-cell leukemia in a natural killer and T cell-dependent manner. The DDR partia...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.24438

    authors: Tang ML,Gasser S

    更新日期:2013-06-01 00:00:00

  • PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.

    abstract::PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.1.1.17824

    authors: Karwacz K,Arce F,Bricogne C,Kochan G,Escors D

    更新日期:2012-01-01 00:00:00

  • In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer.

    abstract::Metastatic breast cancer remains an incurable disease. Most patients experience objective treatment responses associated with palliation of symptoms; however, progression inevitably occurs. Thus, there is an urgent need for innovative therapeutic strategies that may halt disease progression. Adoptive T-cell therapy is...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1055061

    authors: Thakur A,Lum LG

    更新日期:2015-07-15 00:00:00

  • BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis.

    abstract::Langerhans cell histiocytosis (LCH) is a neoplasm of myeloid origin characterized by a clonal proliferation of CD1a(+)/CD207(+) dendritic cells. Recurrent BRAF V600E mutation has been reported in LCH. In the present report, we confirm the feasibility of the high-specificity monoclonal antibody VE1 for detecting BRAF V...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1185582

    authors: Zeng K,Wang Z,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Y,Yu Z,Yan Q,Guo S,Wei J,Guo Y

    更新日期:2016-06-14 00:00:00

  • Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase.

    abstract::Tumor-associated macrophages play a central role in tumor progression and metastasis. Macrophages can also promote the resistance of malignant cells to chemotherapy by stimulating the upregulation of cytidine deaminase, an intracellular enzyme that catabolizes the active form of gemcitabine. Targeting macrophage-depen...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27231

    authors: Amit M,Gil Z

    更新日期:2013-12-01 00:00:00

  • Oncolytic viruses: how "lytic" must they be for therapeutic efficacy?

    abstract::Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or augmentation of a host antitumor immune response is now considere...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2019.1596006

    authors: Davola ME,Mossman KL

    更新日期:2019-03-28 00:00:00

  • High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes.

    abstract::The presence of tumor-infiltrating lymphocytes (TILs) is a strong prognostic parameter for local dissemination and overall survival in melanoma. Lymphocyte migration from blood into peripheral tissues is mainly regulated by vascular endothelium. However, the blood vessels and mechanisms governing the recruitment of TI...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.20492

    authors: Martinet L,Le Guellec S,Filleron T,Lamant L,Meyer N,Rochaix P,Garrido I,Girard JP

    更新日期:2012-09-01 00:00:00

  • Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.

    abstract::Cutaneous angiosarcoma (CAS) is a malignant sarcoma with poor prognosis. Programmed cell death-1 (PD-1)/programmed cell death-1 ligand-1 (PD-L1) expression reflects antitumor immunity, and is associated with patient prognosis in various cancers. The purpose of this study is to investigate the relationship between PD-1...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1253657

    authors: Honda Y,Otsuka A,Ono S,Yamamoto Y,Seidel JA,Morita S,Hirata M,Kataoka TR,Takenouchi T,Fujii K,Kanekura T,Okubo Y,Takahashi K,Yanagi T,Hoshina D,Hata H,Abe R,Fujimura T,Funakoshi T,Yoshino K,Masuzawa M,Amoh Y,T

    更新日期:2016-11-04 00:00:00

  • PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression.

    abstract::Under physiological conditions, PD-1/PD-L1 interactions regulate unwanted over-reactions of immune cells and contribute to maintain peripheral tolerance. However, in tumor microenvironment, this interaction may greatly compromise the immune-mediated anti-tumor activity. PD-1+ NK cells have been detected in high percen...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1557030

    authors: Mariotti FR,Petrini S,Ingegnere T,Tumino N,Besi F,Scordamaglia F,Munari E,Pesce S,Marcenaro E,Moretta A,Vacca P,Moretta L

    更新日期:2018-12-25 00:00:00

  • Overcoming immunosuppression to enhance a p53MVA vaccine.

    abstract::A Phase I trial of a p53-targeting modified vaccinia Ankara (p53MVA) vaccine in patients afflicted with refractory gastrointestinal cancers demonstrated enhanced T-cell recognition of p53 following vaccination. However, this effect was transient suggesting that p53MVA requires combination with immunomodulatory agents ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/21624011.2014.958949

    authors: Hardwick N,Chung V,Cristea M,Ellenhorn JD,Diamond DJ

    更新日期:2014-12-15 00:00:00

  • Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.

    abstract::Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment. Using two mouse models (RET transgenic melanoma and Panc02 orthotopic pancreatic adenocarcinoma), we identified an elevated frequency of ectonucleotidase-expr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1744946

    authors: Shevchenko I,Mathes A,Groth C,Karakhanova S,Müller V,Utikal J,Werner J,Bazhin AV,Umansky V

    更新日期:2020-04-09 00:00:00

  • Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.

    abstract::Prolonged lymphopenia correlating with decreased survival commonly occurs among glioma patients undergoing radiation therapy (RT) and temozolomide (TMZ) treatment. To better understand the pathophysiology of this phenomenon, we prospectively monitored serum cytokine levels and lymphocyte subsets in 15 high-grade gliom...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27357

    authors: Ellsworth S,Balmanoukian A,Kos F,Nirschl CJ,Nirschl TR,Grossman SA,Luznik L,Drake CG

    更新日期:2014-01-01 00:00:00

  • Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

    abstract::The prostaglandin (PG) synthetase cyclooxygenase 2 (Cox-2) promotes tumorigenesis, tumor progression, and metastasis in a variety of human cancer entities including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrate that in PDAC cells such as Colo357 cells, enhanced Cox-2 expression and increased r...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/2162402X.2014.988460

    authors: Gonnermann D,Oberg HH,Kellner C,Peipp M,Sebens S,Kabelitz D,Wesch D

    更新日期:2015-01-07 00:00:00

  • Immune effectors responsible for the elimination of hyperploid cancer cells.

    abstract::The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1463947

    authors: Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

    更新日期:2018-05-21 00:00:00

  • The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions.

    abstract::The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictiv...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2020.1796003

    authors: Lanzi A,Sinicrope FA,Benson AB,Galon J

    更新日期:2020-07-20 00:00:00

  • Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.

    abstract::Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges that are even more significant. In order to devise a treatment strategy for patients with glioblastoma...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1434464

    authors: Suryadevara CM,Desai R,Abel ML,Riccione KA,Batich KA,Shen SH,Chongsathidkiet P,Gedeon PC,Elsamadicy AA,Snyder DJ,Herndon JE 2nd,Healy P,Archer GE,Choi BD,Fecci PE,Sampson JH,Sanchez-Perez L

    更新日期:2018-02-21 00:00:00

  • EBV infection determines the immune hallmarks of plasmablastic lymphoma.

    abstract::Despite recent therapeutic progress, plasmablastic lymphoma (PBL), a distinct entity of high grade B cell lymphoma, is still an aggressive lymphoma with adverse prognosis. PBL commonly occurs in patients with HIV infection and PBL cells frequently express Epstein Barr virus (EBV) genome with type I latency. Occasional...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1486950

    authors: Gravelle P,Péricart S,Tosolini M,Fabiani B,Coppo P,Amara N,Traverse-Gléhen A,Van Acker N,Brousset P,Fournie JJ,Laurent C

    更新日期:2018-07-30 00:00:00

  • Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer.

    abstract::Th2-type inflammation has been proposed to facilitate tumor growth. In De Monte et al. (J Exp Med 208:469-478, 2011) we identify in pancreatic cancer a complex cytokine/chemokine cross-talk within the tumor microenvironment mediating Th2 immune-deviation and show that the ratio of Th2/Th1 tumor infiltrating lymphocyte...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.1.1.17939

    authors: Protti MP,De Monte L

    更新日期:2012-01-01 00:00:00

  • Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model.

    abstract::LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1338236

    authors: Nestvold J,Wang MY,Camilio KA,Zinöcker S,Tjelle TE,Lindberg A,Haug BE,Kvalheim G,Sveinbjørnsson B,Rekdal Ø

    更新日期:2017-06-16 00:00:00

  • Absence of myeloperoxidase and CD8 positive cells in colorectal cancer infiltrates identifies patients with severe prognosis.

    abstract::Colorectal cancer (CRC) infiltration by cells expressing myeloperoxidase (MPO) or CD8 positive T lymphocytes has been shown to be independently associated with favorable prognosis. We explored the relationship occurring between CD8+ and MPO+ cell CRC infiltration, its impact on clinical-pathological features and its p...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1050574

    authors: Däster S,Eppenberger-Castori S,Hirt C,Soysal SD,Delko T,Nebiker CA,Weixler B,Amicarella F,Iezzi G,Governa V,Padovan E,Mele V,Sconocchia G,Heberer M,Terracciano L,Kettelhack C,Oertli D,Spagnoli GC,von Holzen U,Tornil

    更新日期:2015-05-29 00:00:00

  • Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferation.

    abstract::Estrogen receptors have recently been demonstrated at the cell surface. Unlike nuclear receptors, they are able to trigger rapid responses inside the cells. In this study, we evaluated the presence and the possible role of autoantibodies specific to estrogen receptor (anti-ER Abs) in the peripheral blood of breast can...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1074375

    authors: Maselli A,Capoccia S,Pugliese P,Raggi C,Cirulli F,Fabi A,Malorni W,Pierdominici M,Ortona E

    更新日期:2015-08-12 00:00:00

  • ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism.

    abstract::Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components. These changes can directly influence epitope presentation and t...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1336594

    authors: Steinbach A,Winter J,Reuschenbach M,Blatnik R,Klevenz A,Bertrand M,Hoppe S,von Knebel Doeberitz M,Grabowska AK,Riemer AB

    更新日期:2017-06-20 00:00:00